Ultra-thin IOL can be placed easily through 1.5-mm incision
December 15th 2002Nice, France-An innovative ultra-thin, small-incision IOL featuring a unique optical system addresses existing limitations of IOL technology and has the potential to revolutionize cataract and phakic refractive IOL surgery, according to J. Charles Casebeer, MD, at the XX Congress of the European Society of Cat-aract and Refractive Surgeons.
Posterior polar cataract presents management challenge
December 15th 2002Posterior polar cataracts represent one of the more challenging cases for cataract surgeons. The difficulty with these cataracts stems from a frank defect or abnormal attenuation in the posterior capsule in the region of the polar cataract and an increased risk of posterior capsule rupture at any stage of the lens extraction procedure.
Technology making waves in refractive surgery
December 15th 2002Like other areas of ophthalmology, refractive surgery enjoyed a number of refinements and advancements over the past year, including the FDA approval of both wavefront technology and conductive keratoplasty for hyperopia, and advances in refractive IOLs, among others. However, wavefront technology took center stage as the development cited as having the most potential benefit for patients undergoing refractive procedures. Several refractive surgeons weigh in on advances in their subspecialty in 2002.
Phakic IOLs offer promise from a U.S. surgeon's perspective
December 15th 2002In a recent Market Scope report onphakic IOLs, editor David Harmon observes: "Phakic IOLs have become a standard part of the European ophthalmologist's tool kit. CE Mark regulatory approval has been granted to four manufacturers of the devices . . . Europe has become the center of worldwide phakic IOL clinical experience . . . European surgeons implanted an estimated 15,350 phakic IOLs last year."
Anecortave acetate administration shows promise for subfoveal, exudative AMD
December 1st 2002San Francisco-The angiostatic steroid anecortave acetate continues to show promise as a safe and effective treatment for subfoveal, exudative age-related macular degeneration (AMD), according to results from an interim analysis of an ongoing phase II trial.
Extending optical zone may reduce postoperative glare
December 1st 2002Nice, France-By extending the ablation optical zone and overall treatment zone, physicians may be able to decrease the frequency and severity of glare, according to early results from a study of patients treated with the VISX STAR S3 laser.
Large ablation, transition zones improve LASIK results
December 1st 2002San Diego-A large ablation zone and a transition zone are two factors that, when combined during LASIK, seem to decrease the number of patient complaints about the quality of vision in the early postoperative period, according to Steven C. Schallhorn, MD.
Microkeratome-like device holds promise for cell harvesting
December 1st 2002Irvine, CA-A modified microkeratome shows promise for making the task of limbal stem cell harvesting simpler, better, and more efficient, said Roy S. Chuck, MD, PhD, who has been involved in the development of this instrument.
Epithelial ingrowth protocol guides intervention, therapy
December 1st 2002Nice, France-Although the incidence of epithelial ingrowth as a complication of LASIK is declining, considerable uncertainty remains over when to intervene, according to Arun C. Gulani, MD. In response, Dr. Gulani has devised a grading system to help surgeons answer that question by placing values on the density of the epithelial ingrowth
2002: Specialists pleased with ongoing retinal progress
December 1st 2002Therapies for retinal diseases that re-mained untreatable for decades are seeing major advances. So much so that Jason Slakter, MD, clinical professor of ophthalmology, New York University School of Medicine, and surgeon director, Manhattan Eye, Ear, & Throat Hospital, New York, has proclaimed the first years of the new mil-lennium as the "Decade of the Macula."
CMV retinitis treatment responding to changing HIV therapy
December 1st 2002Editor's Note: HIV/AIDS continues to be a major health problem, not only in the developing world, but in North America and Europe as well. Although the incidence of ocular complications of HIV/AIDS has decreased dramatically since the introduction of highly active anti-retroviral therapy (HAART), the prevalence of HIV positivity continues toincrease, particularly among heterosexual women and minorities.
2002: research confirms benefit of IOP-lowering treatment
December 1st 2002Publication of results from the Ocular Hypertension Treatment Study (OHTS) and the Early Manifest Glaucoma Trial (EMGT) represents two of the most notable events occurring in the field of glaucoma in 2002, but the year is also marked by a number of other significant developments with the potential to influence patient evaluation and management.
Task force suggests new grading scale for diabetic retinopathy
December 1st 2002Orlando-A task force composed of 30 leading ophthalmologists and retinal specialists is recommending the use of a new, five-level classification system for distinguishing degrees of diabetic retinopathy. The results of this effort were highlighted at a news conference held during the American Academy of Ophthalmology (AAO) annual meeting in Orlando.
Expanded applications explored for femtosecond laser
December 1st 2002Carlsbad, CA-The Pulsion FS femtosecond laser keratome (IntraLase Corp., Irvine, CA) appears to be an important new instrument for use in the treatment of lamellar keratoplasty, among others, according to Lee T. Nordan, MD, who described his preliminary results.
Grant funds research: Daniel Albert, MD, wins lifetime achievement prize
December 1st 2002Orlando-Daniel M. Albert, MD, has won the Fight for Sight/Mildred Weisenfeld Award for Lifetime Achievement in Vision Research, which includes a $50,000 grant for research endeavors. The award was presented at the annual meeting of the American Academy of Ophthalmology.
Precision key to effectiveness of custom ablation
November 15th 2002Nice, France-Custom ablation is a useful technique for eyes that have not been treated with a refractive procedure. But this approach can also be used to improve the quality of vision in previously treated eyes that exhibit symptoms such as glare, halos, night vision difficulties, or monocular diplopia, according to Omar J. Hakim, MD, who spoke during the XX Congress of the European Society of Cataract and Refractive Surgeons (ESCRS).
Glaucoma agents effective in reducing diurnal, trough IOPs
November 15th 2002Charleston, SC-When prescribing brimonidine 0.2% b.i.d. as monotherapy for ocular hypertension or primary open-angle glaucoma, physicians should make sure that the drug maintains its effectiveness in the late afternoon and may want to add a third drop to the daily dosage, said William C. Stewart, MD.